BiotechTube

ZP4207 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypoglycemia

Conditions

Hypoglycemia

Trial Timeline

Apr 1, 2015 → Aug 1, 2015

NCT ID
NCT02390141

About ZP4207 + Placebo

ZP4207 + Placebo is a phase 1 stage product being developed by Zealand Pharma for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02390141. Target conditions include Hypoglycemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02390141Phase 1Completed

Competing Products

20 competing products in Hypoglycemia

See all competitors
ProductCompanyStageHype Score
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
Nasal GlucagonEli LillyPhase 3
77
Glucagon + InsulinAbvance TherapeuticsPhase 1
25
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 1
33
Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mgEli LillyPhase 2
52
Nasal GlucagonEli LillyPhase 3
77
Eplerenone + PlaceboJohnson & JohnsonPre-clinical
23
Sitagliptin phosphate + PlaceboMerckApproved
85
PasireotideNovartisPhase 1
33
DasiglucagonNovo NordiskPhase 3
76
Glucagen + Mayne GlucagonPfizerPhase 1
32
PramlintideBristol Myers SquibbApproved
84
dasiglucagon + placebo + GlucaGen HypoKitZealand PharmaPhase 3
74
Dasiglucagon + PlaceboZealand PharmaPhase 1
30
Dasiglucagon + Dasiglucagon + PlaceboZealand PharmaPhase 2
49
ZP4207 + GlucagonZealand PharmaPhase 1
30
Dasiglucagon + PlaceboZealand PharmaPhase 3
74
dasiglucagon + GlucaGenZealand PharmaPhase 3
74
Dasiglucagon + PlaceboZealand PharmaPhase 2
49

Other Products from Zealand Pharma

glepaglutidePhase 3
74
GlepaglutidePhase 3
74
dasiglucagon + placebo + GlucaGen HypoKitPhase 3
74
glepaglutide + PlaceboPhase 3
74
GlepaglutidePhase 3
74